North America Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask a question about the cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market
North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market highlights
- The North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market generated a revenue of USD 3,473.2 million in 2024.
- The market is expected to grow at a CAGR of 6.1% from 2025 to 2035.
- In terms of segment, cervical cancer screening was the largest revenue generating type in 2024.
- Cervical Cancer Screening is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2025 to 2035.
North America data book summary
| Market revenue in 2024 | USD 3,473.2 million |
| Market revenue in 2035 | USD 6,600.7 million |
| Growth rate | 6.1% (CAGR from 2025 to 2035) |
| Largest segment | Cervical cancer screening |
| Fastest growing segment | Cervical Cancer Screening |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment |
Other key industry trends
- In terms of revenue, North America region accounted for 41.2% of the global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2035.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,288.6 million by 2035.
North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market Growing significantly. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs.
These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations.
To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma.
No credit card required*
Publish Date: Apr 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Scope
Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Becton Dickinson & Co | View profile | 73,000 | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 | www.bd.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Hologic Inc | View profile | 6,990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | www.hologic.com |
| CooperSurgical | View profile | 501-1000 | Trumbull, Connecticut, United States, North America | www.coopersurgical.com |
| Utah Medical Products Inc | View profile | 190 | 7043 South 300 West, Midvale, UT, United States, 84047 | www.utahmed.com |
| MedGyn Products | View profile | 51-100 | Addison, Illinois, United States, North America | www.medgyn.com |
North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook will help companies and investors design strategic landscapes.
Cervical Cancer Screening was the largest segment with a revenue share of 51.36% in 2024.
Horizon Databook has segmented the North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market based on cervical cancer screening, cervical cancer diagnostics, pre-cancerous lesion treatment covering the revenue growth of each sub-segment from 2018 to 2035.
North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market Growing significantly. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs.
These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations.
To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma.
- North America Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Type Outlook (Revenue, USD Million , 2018-2035)
- Cervical Cancer Screening
- Cervical Cancer Diagnostics
- Pre-cancerous Lesion Treatment
Reasons to subscribe to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook
- Our clientele includes a mix of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook from 2018 to 2035, including revenue numbers, major trends, and company profiles.
North America Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market, 2018-2035 (US$M)
North America Type - Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Statistics, 2024 - 2035 (US$M)
